On the evening of February 8th, 65438, People's Daily reported that the first COVID-19 neutralizing antibody combination therapy drug with independent intellectual property rights in China was approved. On the 9th, Professor Zhang of Tsinghua University Medical College, who is leading the research and development of this specific drug, introduced it to the reporter. The approval indicates that China has the first independently developed specific anti-COVID-19 drug, and its effectiveness has been proved by randomized, double-blind and placebo-controlled studies. Zhang said that specific drugs can provide treatment and prevention, and one injection can last for 9 months or even 1 year.

China Pharmaceutical Products Administration officially approved two kinds of COVID-19-specific drugs: 1. COVID-19 neutralizing antibody? Combination therapy: Ambaviruzumab injection (BRII-196); 2. Romivir Injection (BRII- 198).

What is the applicable population and effectiveness of these COVID-19 specific drugs approved in China?

① Applicable age: COVID-19 specific drugs can be used to treat adults and adolescents who have positive COVID-19 test results and have developed into severe coronavirus pneumonia-19 risk factors. That is,/kloc-people over 0/2 years old. Teenagers are suitable for patients 12 ~ 17 years old and weighing ≥40Kg. Unlike COVID-19 vaccine, COVID-19 specific drug is suitable for people over 12 years old. No longer vaccinate in batches and stages like COVID-19 vaccine.

② Effectiveness: At present, specific drugs have been studied in11clinical trial institutions in six countries on four continents. The results of the third phase clinical trial showed that zero death was achieved after 28 days of treatment, and 8 cases died in the control group. The antibody combination medicine can effectively reduce the risk of hospitalization and death of 80% of high-risk outpatients in COVID-19. Clinical results show that it can treat mild, common and serious symptoms. Especially for patients with 5- 10 days of onset, the effect is remarkable. The sooner it is found, the higher the cure rate.

③ In order to fight the epidemic and end it as soon as possible, since March 2020, Tsinghua University, Shenzhen Third People's Hospital and Tengshengbo Medical have jointly developed COVID-19 specific drugs for the first time in China. After nearly two years, the final phase III clinical trial results confirmed that COVID-19's specific drugs also had effects on mutants and Delta.

In view of the Delta mutant in China at present, Tengshengbo Medicine donated nearly 3,000 copies of monoclonal antibody injection of Ambavavir and monoclonal antibody of Romovir, and treated nearly 900 patients. It has become the COVID-19 specific medicine for the largest patient group in the world. Zhang Zheng, president of Shenzhen Third People's Hospital, said that at present, besides basic treatment, the treatment of COVID-19 patients is mainly divided into antiviral treatment and anti-inflammatory treatment.

Oral drugs are also an important part of the research and development of special drugs in COVID-19. At present, 20 oral drug projects in COVID-19 have entered the third clinical phase. There are two in China.

Hope is just around the corner, everyone should take preventive measures and everyone should abide by them.